"instanceType","text","label","uuid:ID","description","name","id"
"Objective","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","","bfca12dc-092d-4daf-9888-ff5834ca9ba2","Main objective","OBJ1","Objective_1"
"Objective","To document the safety profile of the xanomeline TTS.","","bf97b018-9a84-4bb4-811a-c916aa7d2447","Safety","OBJ2","Objective_2"
"Objective","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","","16ad14f1-7346-4e3e-abe9-8fb2a3505116","Behaviour","OBJ3","Objective_3"
"Objective","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","","7fc23584-a2a6-4d86-ba0b-d5f08d3553e3","","OBJ4","Objective_4"
"Objective","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","","00fdbb50-b2d6-456b-8462-1177c6dbec97","","OBJ5","Objective_5"
"Objective","To assess the treatment response as a function of Apo E genotype.","","61ce219f-a8b4-4e2f-b9d4-912613a1677b","","OBJ6","Objective_6"
